ESLA · Estrella Immunopharma, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As a result, management has determined that there is a substantial doubt about its ability to continue as a going concern.”View the 10-Q filed May 18, 2026
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ESLA
this stock
Estrella Immunopharma, Inc.
|
$31.09M | -53.7% | — | — | 0.1% |
|
ONC
BeOne Medicines Ltd.
|
$514.79B | +14.6% | +22179.2% | 791.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$125.73B | +9.4% | +46.2% | 28.9 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.75B | +1.9% | +20.8% | 19.4 | 3.4% |
|
ARGX
Argenx SE
|
$54.12B | +2.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ESLA | +1.2% | -22.1% | -42.9% | +1.2% | -53.7% |
| SPY | +3.5% | +2.4% | +13.4% | +3.5% | +13.4% |
| vs SPY | -2.3% | -24.5% | -56.3% | -2.3% | -67.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.